Chapter 1 Metabolic Disorder Drugs Market Overview
1.1 Metabolic Disorder Drugs Definition
1.2 Global Metabolic Disorder Drugs Market Size Status and Outlook (2018-2032)
1.3 Global Metabolic Disorder Drugs Market Size Comparison by Region (2018-2032)
1.4 Global Metabolic Disorder Drugs Market Size Comparison by Type (2018-2032)
1.5 Global Metabolic Disorder Drugs Market Size Comparison by Application (2018-2032)
1.6 Global Metabolic Disorder Drugs Market Size Comparison by Sales Channel (2018-2032)
1.7 Metabolic Disorder Drugs Market Dynamics
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Merger/Acquisition/Expansion)
1.7.4 Key Trends in Metabolic Disorder Drugs Market
Chapter 2 Metabolic Disorder Drugs Market Competition by Player
2.1 Global Metabolic Disorder Drugs Sales and Market Share by Player (2021-2023)
2.2 Global Metabolic Disorder Drugs Revenue and Market Share by Player (2021-2023)
2.3 Global Metabolic Disorder Drugs Average Price by Player (2021-2023)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Metabolic Disorder Drugs Market Segment by Type
3.1 Global Metabolic Disorder Drugs Market by Type
3.1.1 Oral
3.1.2 Parenteral
3.1.3 Others
3.2 Global Metabolic Disorder Drugs Sales and Market Share by Type (2018-2023)
3.3 Global Metabolic Disorder Drugs Revenue and Market Share by Type (2018-2023)
3.4 Global Metabolic Disorder Drugs Average Price by Type (2018-2023)
3.5 Conclusion of Segment by Type
Chapter 4 Metabolic Disorder Drugs Market Segment by Application
4.1 Global Metabolic Disorder Drugs Market by Application
4.1.1 Lysosomal Storage Diseases
4.1.2 Diabetes
4.1.3 Obesity
4.1.4 Inherited Metabolic Disorders
4.1.5 Hypercholesterolemia
4.2 Global Metabolic Disorder Drugs Revenue and Market Share by Application (2018-2023)
4.3 Conclusion of Segment by Application
Chapter 5 Metabolic Disorder Drugs Market Segment by Sales Channel
5.1 Global Metabolic Disorder Drugs Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Metabolic Disorder Drugs Revenue and Market Share by Sales Channel (2018-2023)
5.3 Conclusion of Segment by Sales Channel
Chapter 6 Metabolic Disorder Drugs Market Segment by Region & Country
6.1 Global Metabolic Disorder Drugs Market Size and CAGR by Region (2018-2032)
6.2 Global Metabolic Disorder Drugs Sales and Market Share by Region (2018-2023)
6.3 Global Metabolic Disorder Drugs Revenue and Market Share by Region (2018-2023)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Metabolic Disorder Drugs Market Share by Type
6.4.3 North America Metabolic Disorder Drugs Market Share by Application
6.4.4 United States
6.4.5 Canada
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Metabolic Disorder Drugs Market Share by Type
6.5.3 Europe Metabolic Disorder Drugs Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Spain
6.5.9 Russia
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Metabolic Disorder Drugs Market Share by Type
6.6.3 Asia-Pacific Metabolic Disorder Drugs Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Metabolic Disorder Drugs Market Share by Type
6.7.3 South America Metabolic Disorder Drugs Market Share by Application
6.7.4 Brazil
6.7.5 Mexico
6.7.6 Argentina
6.7.7 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Metabolic Disorder Drugs Market Share by Type
6.8.3 Middle East & Africa Metabolic Disorder Drugs Market Share by Application
6.8.4 Turkey
6.8.5 UAE
6.8.6 Saudi Arabia
6.8.7 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Metabolic Disorder Drugs Players
7.1 AbbVie
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.2 Actelion Pharmaceuticals
7.3 Amgen
7.4 Astra Zeneca
7.5 Biocon
7.6 BioMarin Pharmaceutical
7.7 Boehringer Ingelheim
7.8 Bristol-Myers Squibb
7.9 Cipla
7.10 CymaBay Therapeutics
7.11 Eli Lilly
7.12 Fuji Yakuhin
7.13 KOWA
7.14 Kythera
7.15 LG Life Science
7.16 Merck
7.17 Metsubishi Tanabe Pharma
7.18 Novartis
7.19 Novo Nordisk
7.20 Sanofi
7.21 Shire PLC
7.22 Takeda Pharmaceutical
Chapter 8 Upstream and Downstream Analysis of Metabolic Disorder Drugs
8.1 Industrial Chain of Metabolic Disorder Drugs
8.2 Upstream of Metabolic Disorder Drugs
8.3 Downstream of Metabolic Disorder Drugs
Chapter 9 Development Trend of Metabolic Disorder Drugs (2024-2032)
9.1 Global Metabolic Disorder Drugs Market Size (Sales and Revenue) Forecast (2024-2032)
9.2 Global Metabolic Disorder Drugs Market Size and CAGR Forecast by Region (2024-2032)
9.3 Global Metabolic Disorder Drugs Market Size and CAGR Forecast by Type (2024-2032)
9.4 Global Metabolic Disorder Drugs Market Size and CAGR Forecast by Application (2024-2032)
9.5 Global Metabolic Disorder Drugs Market Size and CAGR Forecast by Sales Channel (2024-2032)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
